<DOC>
	<DOCNO>NCT03053271</DOCNO>
	<brief_summary>This Phase 2 multicenter , randomize , double-blind , placebo control study ATR-101 evaluate efficacy safety orally-administered ATR-101 adult endogenous Cushing 's syndrome . Following wash-out , eligible subject undergo 6-week open-label dose escalation ATR-101 . Subjects continue eligible undergo 4-week randomize withdrawal period . It anticipate overall duration study per subject range approximately 14-20 week .</brief_summary>
	<brief_title>A Study ATR-101 Treatment Endogenous Cushing 's Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cushing Syndrome</mesh_term>
	<criteria>Confirmed diagnosis endogenous Cushing 's syndrome Baseline UFC 1.3 10 Ã— upper limit normal ( ULN ) If previous pituitary surgery , participant must least 6 month since surgery time screen BMI 18 45 kg/m2 , inclusive PseudoCushing 's syndrome , cyclic Cushing 's syndrome current iatrogenic Cushing 's syndrome Candidates surgical treatment Cushing 's syndrome , unless surgery anticipate occur study Normal late night salivary cortisol 24hr urine free cortisol Radiotherapy pituitary within 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Endogenous Cushing 's Syndrome</keyword>
	<keyword>ATR-101</keyword>
	<keyword>CS</keyword>
</DOC>